



heliospectra

Heliospectra AB (publ)

Financial Statement Bulletin 2014

Heliospectra AB (publ)
Reg. No. 556695-2205
Box 5401
SE-402 29 Gothenburg
Phone: +46 (0)31 - 40 67 10
www.heliospectra.com

Financial Statement Bulletin 2014, page 1/9

- Heliospectra underwent an oversubscribed share issue of around MSEK 40.9 gaining about 400 new shareholders and on 18 June 2014, was listed on First North and by the end of 2014, the number of new shareholders had risen to over 1000.
- The new product series LX60 was launched, with the first installation at Swedeponic, the largest grower of fresh herbs in Europe.
- Heliospectra's breakthrough order in the USA - the first partial order worth SEK 200,000
- Heliospectra offer the option of trading in the company's shares in the US via a so-called American Depositary Receipt (ADR) by listing on OTC Markets under OTCQB with BNY Mellon as principal and Merriman as the broker.
- Heliospectra's first patent, which has previously been approved in China, Russia and Hong Kong, has now also been approved in the USA.

July - December:

- Net turnover was KSEK 1,247 (289)
- Operating profit/loss was KSEK -14,072 (-5,258)
- Profit/loss after tax was, SEK -14,068 (-5,266) or SEK -1 (-662) per share
- Operating cash flow was KSEK -15,627 (-4,770)

January - December

- Net turnover was KSEK 3,110 (486)
- Operating profit/loss was KSEK -32,901 (-17,141)
- Profit/loss after tax was, SEK -33,670 (-17,117) or SEK -2 (-2,150) per share
- Operating cash flow was KSEK -32,668 (-9,656)

Events after the period:

- Heliospectra receives an order to the value of ca. SEK 1 million from an existing customer for the cultivation of medicinal plants.
- The company has secured loan financing to compensate for the negative cash flow.

Heliospectra AB (publ)
Year End Report 2014

CEO's comments:

2014 has been an eventful year for Heliospectra. We have gained over 1,000 shareholders, many of whom actively follow the company's growth after our listing in the summer. At the same time, we have implemented various initiatives to attract investors and strategic partners on the US market where Heliospectra is receiving great interest with its strong brand, top-ranking products, an expressed SaaS strategy as well as a focus on sustainable food production. The objective is to create a good foundation for our continued expansion.

During the latter part of 2014, we have commenced the launch of our new products LX60 and RX30 series based on the same technical platform in order to achieve economies of scale. In North America, Professor Bruce Bugbee has noted that we have one of the best products on the market and this has been further confirmed by initial orders from strategically important customers. The collaboration with international actors such as MIT Media Lab and the German Aerospace Centre DLR are indications of our innovative ability to develop world-leading technology.

Moving forward, we will focus on marketing and sales, primarily in the North American market, but also in the Europe. North America is expanding, in particular within the field of medicinal plants, although we have also noted an increasing demand from traditional greenhouses and new applications such as cultivation near to larger food stores.

We have built up a strong, competent team with international staff who are all passionate about their work. World-leading technology, a market with rapid growth, competent staff and strong main shareholders is a winning combination.

Staffan Hillberg, CEO
Heliospectra AB

Important events January - December

- Heliospectra completed an oversubscribed issue at approximately SEK 40.9 million, with approximately 400 new shareholders
- Heliospectra was listed on First North on 18 June, 2014
- The new product series LX60 was launched, with the first installation at Swedeponic, the largest grower of fresh herbs in Europe with brands such as Santa Maria and Spisa.
- Heliospectra's breakthrough order in the USA - the first partial order worth SEK 200,000
- Heliospectra participates in projects relating to the use of algae for water purification, with financing from Vinnova of MSEK 10 and Lund Council as the principal.
- Heliospectra partner is a EUR 4,5 million project financed by the EU for cultivation in space along with the German Aerospace Centre DLR
- Heliospectra provides the opportunity to trade in company shares in the US via a so-called American Depositary Receipt (ADR) by listing on the OTC Markets under OTCQB with BNY Mellon as the account-holding institution and Merriman as the broker.
- Heliospectra launches its own web shop in order to be able to receive its own, small orders from around the world.
- Heliospectra's first patent, which has previously been approved in China, Russia and Hong Kong, has now also been approved in the US.
- Heliospectra's co-operation with MIT Media Lab regarding future production of food is highlighted in the international magazine [Wired](http://www.wired.co.uk/magazine/archive/2014/10/features/server-farm) www.wired.co.uk/magazine/archive/2014/10/features/server-farm
- New customer categories are added, primarily in the US, and this is reflected in an order from Google USA of four units of the new product RX30.

Financial report

Turnover and profit/loss July - December

Net turnover was KSEK 1,247 (289) Operating profit/loss was KSEK -14,072 (-5,258), involving a negative operating margin (neg). Profit/loss after tax was, KSEK -14,068 (-5,266) or SEK -1 (-662) per share.

Turnover and profit/loss January - December

Net turnover was KSEK 3,110 (486) Operating profit/loss was KSEK -32,901 (-17,141), involving a negative operating margin (neg). Profit/loss after tax was, SEK-33,670 (-17,117) or SEK -2 (-2,150) per share.

Cash flow July - December

Operating cash flow was KSEK -15,627 (-4,770). Total cash flow was KSEK -17,431 (-2,400). During Q3-Q4, Heliospectra invested in securing materials and production which had a negative impact on the cash flow of KSEK 2,653.

Cash flow January - December

Operating cash flow was KSEK -32,668 (-9,656). Total cash flow was KSEK 2,596 (2,671).

Significant risks and uncertainties

For a comprehensive, though not exhaustive summary of risks, please refer to Heliospectra's prospectus April/May 2014, pages 9-12, <http://ir.heliospectra.com/aktien/prospekt>.

Events after the period

- Heliospectra received an order to the value of ca. SEK 1 million from an existing customer for the cultivation of medicinal plants.
- The company secured loan financing to compensate for the negative cash flow.

Future prospects

The upcoming period will focus on the sales and marketing side. We have secured a supply capacity that can meet substantial volumes, we negotiate directly with large strategic customers and we are building up an international distributor and retail network. The priority markets that we are working with are Europe and North America and we particularly see very strong growth in North America. We also intend expanding the cooperation with a number of strategic partners that will provide us with greater market presence and more inputs on the market. Overall, the company is well positioned to begin to capitalize on the market potential that we address with our products.

The board makes no quantified forecast for 2015.

Upcoming reporting dates

- Quarterly report Q1 30/4/2015
- Annual General Meeting 5/6/2015
- Half-year report January-June 31/8/2015
- Quarterly report July-September 26/10/2015
- Financial statement bulletin 2015 26/02/2015

Gothenburg 26 February 2015,

The board

Group's profit and loss account <i>Amounts in thousands of kronor (SEK)</i>	2014 July-Dec	2013 July-Dec	2014 Jan-Dec	2013 Jan-Dec
Net turnover	1,247	289	3,110	486
Other operating income	768	550	1,217	722
	2,015	839	4,327	1,208
Operating expenses				
Commodities	-1,127	-194	-2,484	-301
Other external costs	-7,667	-2,294	-20,030	-8,444
Staffing costs	-5,641	-2,266	-11,097	-6,919
Depreciation and amortization	-1,652	-1,343	-3,617	-2,685
Earnings before interest and taxes	-14,072	-5,258	-32,901	-17,141
Operating margin	neg	neg	neg	neg
Total financial items	4	-8	-769	24
Profit/loss before tax	-14,068	-5,266	-33,670	-17,117
Tax				
Profit/loss after tax	-14,068	-5,266	-33,670	-17,117

Group's cash flow analysis <i>Amounts in thousands of kronor (SEK)</i>	2014 July-Dec	2013 July-Dec	2014 Jan-Dec	2013 Jan-Dec
Cash flow before changes in operating capital	-12,416	-3,923	-30,053	-14,432
Changes in operating capital	-3,211	-847	-2,615	4,776
Group's cash flow	-15,627	-4,770	-32,668	-9,656
Cash flow from investment activities	-1,902	-7,593	-5,904	-7,619
Cash flow from financing activities	98	9,963	41,168	19,946
Cash flow for the period	-17,431	-2,400	2,596	2,671
Cash and cash equivalents at beginning of period	23,575	5,931	3,531	860
Cash and cash equivalents at end of period	6,144	3,531	6,127	3,531

Ratios	2014 July-Dec	2013 July-Dec	2014 Jan-Dec	2013 Jan-Dec
Turnover per share, SEK	0.1	105	0.3	152
Profit/loss per share after tax, SEK	-1	-662	-2	-2,150
Operating margin, %	neg	neg	neg	neg
EBITDA, KSEK	-12,420	-3,915	-29,284	-14,456
EBITDA margin, %	neg	neg	neg	neg

Note: The figures for 2014 include issue costs of MSEK 5.9 and repayment of bridge loans of MSEK 8

Group's balance sheet <i>Amounts in thousands of kronor (SEK)</i>	12/31/2014	12/31/2013
Assets		
Intangible assets	15,116	12,867
Tangible assets	1,990	1,951
Financial assets		2
Total fixed assets	17,106	14,820
Inventory	4,249	1,990
Current receivables	4,101	1,370
Cash and bank	6,127	3,531
Total current assets	14,477	6,891
Total assets	31,583	21,711
Equity and liabilities		
Equity	16,099	8,724
Long-term liabilities	9,728	9,752
Short-term liabilities	5,756	3,235
Total equity and liabilities	31,583	21,711

Changes in group's equity <i>Amounts in thousands of kronor (SEK)</i>	2014 Jan-Dec	2013 Jan-Dec
Opening equity	8,724	5,834
Net profit for period after tax	-33,670	-17,117
New share issue	666	244
Share Premium Reserve	40,379	19,763
Closing equity	16,099	8,724

Ratios	12/31/2014	12/31/2013
Number of shares, thousands	13,791	7.96
Equity/share, SEK	1	1,096
Solidity	51%	40%
Liquidity	178%	151%

Note: In 2014, in addition to a new issue, a split of 1/1000 was also implemented.

Accounting principles and notes

The company's financial statement bulletin has been drawn up in accordance with the Annual Accounts Act and the Swedish Accounting Standards Board's general advice, BFNAR 2012:1 Annual Report and Consolidated Financial Statements (K3). The accounting principles are unchanged from those applied in the annual report for 2013 and described in the annual report. All amounts are reported in thousands of Swedish kronor (SEK) unless otherwise stated.

Definitions

<u>Turnover per share</u>	<u>Profit/loss per share after tax</u>
Total turnover in relation to number of shares	Profit/loss after tax in relation to number of shares
<u>Operating margin</u>	<u>EBITDA</u>
Operating profit in relation to total turnover	Operating profit excl. depreciation and amortization
<u>EBITDA margin</u>	<u>Equity/share</u>
EBITDA in relation to total turnover	Equity in relation to number of shares
<u>Solidity</u>	<u>Liquidity</u>
Equity in relation to total assets	Current receivables plus cash and cash equivalents in relation to current liabilities

Shares

The shares have been established in accordance with Swedish law and are denoted in Swedish kronor. There is only one share class. The shares are in the name of the holder and the share register is maintained electronically by Euroclear Sweden.

The share capital in Heliospectra amounts to SEK 1,379,119.5 distributed as 13,791,195 shares with a par value of SEK 0.10.

Heliospectra's shares and warrants are traded on First North from 18 June 2014.

Ticker symbol on First North: HELIO

ISIN code for the shares: SE0005933082

Warrants (TO1)

In conjunction with the issues in the spring of 2014, 5,111,195 warrants were issued. Two (2) warrants entitle the holder during the period 1 September to 30 September 2015, to subscribe for one additional new share at SEK 10.00 each.

Ticker symbol for warrants on First North: HELIO TO1

ISIN code for warrants: SE0005933165

Certified Adviser

G&W Fondkommission
111 43 Stockholm

Ownership list

<i>Shareholders</i>	<i>Number of shares</i>	<i>Shareholding</i>
Weland Stål AB	2 866 500	20.8%
The Industrifonden foundation	2 034 000	14.7%
Midroc New Technology AB	1 958 500	14.2%
Gösta Welandsson	1 000 000	7.2%
Weland Värdepapper AB	973 052	7.1%
B.C.L.M.Ä. 2 Förvaltnings AB	797 000	5.8%
Insurance Company Avanza Pension	451 631	3,3%
B.C.L.M.Ä. 6 Förvaltnings AB	419 000	3.0%
PIBA AB	311 000	2.3%
Inkubator i Borås AB	260 000	1,9%
Other shareholders	2 720 512	19,7%
Total:	13 791 195	100.0%

The total number of shareholders is around 1,200.

Stock options for senior management

A resolution was made at the AGM on 7 April 2014 for a stock options programme for senior management and employees. It is made up of 770,000 option where each option entitles the holder to subscribe to one new share at a subscription price of SEK 12 per share during the period from 7 March to 7 May 2016. The dilution from this will be approximately 6%.

Heliospectra in brief

Heliospectra (publ - listed on Nasdaq OMX First North) was founded in 2006 and specializes in intelligent lighting technology for plant research and greenhouse cultivation. Heliospectra products are based on in-depth knowledge of plant physiology and photosynthesis together with a unique method of assimilating modern LED technology. After six years of development in Sweden, the company has now begun to expand on the international market. The company has amassed approximately MUSD 16 of equity and has received over 2.6 million dollars through academic scholarships. Heliospectra has also received numerous awards for its forward thinking technology. For further information, please refer to Heliospectra's prospectus April/May 2014, <http://ir.heliospectra.com/aktien/prospekt/>.

This report has not been reviewed by the company's auditors.

For further information, please contact

CEO Staffan Hillberg, +46 (0)708-365944, staffan@heliospectra.com

Chairman Jan Tufvesson, +46 (0)706-442460, jan.tuf@telia.com

CFO Håkan Bengtsson, +46 (0)705-558902, hakan.bengtsson@heliospectra.com